Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

[1]  L. Sequist,et al.  Afatinib as First‐line Treatment of Older Patients With EGFR Mutation‐Positive Non‐Small‐Cell Lung Cancer: Subgroup Analyses of the LUX‐Lung 3, LUX‐Lung 6, and LUX‐Lung 7 Trials , 2018, Clinical lung cancer.

[2]  C. Rolfo,et al.  ROS-1 Rearrangements in Circulating Tumor Cells. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  C. Paweletz,et al.  Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  N. Rosenfeld,et al.  Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling , 2018, PloS one.

[5]  Benjamin Solomon,et al.  Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  Jia-hua Hu,et al.  Improved detection of EGFR mutations in the tumor cells enriched from the malignant pleural effusion of non-small cell lung cancer patient. , 2018, Gene.

[7]  T. Koessler,et al.  Circulating tumoral DNA: Preanalytical validation and quality control in a diagnostic laboratory. , 2018, Analytical biochemistry.

[8]  Markus Riester,et al.  Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. , 2018, JCO precision oncology.

[9]  J. Pinski,et al.  Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. , 2018, Biochemical and biophysical research communications.

[10]  Ash A. Alizadeh,et al.  Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. , 2017, Cancer Discovery.

[11]  F. Giles,et al.  OA 07.03 Circulating Tumor DNA Mutant Allele Frequency and Tumor Burden as Biomarkers for Response to Immune Checkpoint Blockade , 2017 .

[12]  M. Tiseo,et al.  Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK‐Positive NSCLC With Disease Progression During Crizotinib Treatment , 2017, Clinical lung cancer.

[13]  P. Pauwels,et al.  Exosomes as diagnostic and predictive biomarkers in lung cancer. , 2017, Journal of thoracic disease.

[14]  M. Tiemann,et al.  Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Razelle Kurzrock,et al.  Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy , 2017, Clinical Cancer Research.

[16]  C. Paweletz,et al.  Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients , 2017, Clinical Cancer Research.

[17]  S. Patel,et al.  1331PDetection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Circulating tumour (ct) DNA analysis across 3 platforms , 2017 .

[18]  P. Hegde,et al.  Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK) , 2017, Pneumologie.

[19]  G. Oxnard,et al.  Application of Plasma Genotyping Technologies in Non–Small Cell Lung Cancer: A Practical Review , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  Eduardo Vilar,et al.  Clinical utility of circulating cell-free DNA in advanced colorectal cancer , 2017, PloS one.

[21]  M. Rugge,et al.  Consistency and reproducibility of next‐generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens , 2017, Cancer cytopathology.

[22]  R. Raja,et al.  Abstract 582: Circulating tumor DNA (ctDNA) variant allele frequencies are reduced in responders to durvalumab and low baseline variant allele frequencies are associated with improved overall survival in NSCLC patients , 2017 .

[23]  P. Jänne,et al.  Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  D. Gandara,et al.  Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  D. Ettinger,et al.  Molecular Profiling of Malignant Pleural Effusion in Metastatic Non‐Small‐Cell Lung Carcinoma. The Effect of Preanalytical Factors , 2017, Annals of the American Thoracic Society.

[26]  N. Limdi,et al.  Implementation and utilization of the molecular tumor board to guide precision medicine , 2017, Oncotarget.

[27]  Yi-long Wu,et al.  Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells , 2017, Clinical Cancer Research.

[28]  S. Vowler,et al.  Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial. , 2017 .

[29]  R. Kurzrock,et al.  Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma , 2017, Clinical Cancer Research.

[30]  K. Danenberg,et al.  Correlation of cell-free circulating DNA, RNA, and PD-L1 from plasma with clinical response in patients with metastatic lung and breast cancers. , 2017 .

[31]  A. Drilon,et al.  PD-L1 expression and response to immunotherapy in patients with MET exon 14-altered non-small cell lung cancers (NSCLC). , 2017, Journal of Clinical Oncology.

[32]  G. Tonini,et al.  Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib , 2017, Oncotarget.

[33]  Jedd D. Wolchok,et al.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.

[34]  Nicolai J. Birkbak,et al.  Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[35]  Ashwini Naik,et al.  Phylogenetic ctDNA analysis depicts early stage lung cancer evolution , 2017, Nature.

[36]  M. Erlander,et al.  Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine , 2017, Clinical Cancer Research.

[37]  N. Rosenfeld,et al.  Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  C. Zahnow,et al.  Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. , 2017, Cancer discovery.

[39]  Stefan Sleijfer,et al.  Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions , 2017, Molecular oncology.

[40]  Chia-Chi Lin,et al.  Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[42]  C. Rolfo,et al.  Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer , 2017, Expert review of molecular diagnostics.

[43]  R. Rosell,et al.  Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients , 2017, British Journal of Cancer.

[44]  N. Peled,et al.  Clinical Impact of Hybrid Capture–Based Next‐Generation Sequencing on Changes in Treatment Decisions in Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[45]  V. Gebski,et al.  Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[46]  E. Mardis.  DNA sequencing technologies: 2006–2016 , 2017, Nature Protocols.

[47]  J. Solassol,et al.  Circulating Cell Free Tumor DNA Detection as a Routine Tool for Lung Cancer Patient Management , 2017, International journal of molecular sciences.

[48]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[49]  S. Zöchbauer-Müller.  MTE09.02 Biomarkers for Targeted Therapies and Immune Checkpoint Inhibitors in Advanced NSCLC , 2017 .

[50]  S. Mortimer,et al.  OA06.01 Clinical Utility of Circulating Tumor DNA (ctDNA) Analysis by Digital next Generation Sequencing of over 5,000 Advanced NSCLC Patients , 2017 .

[51]  K. Danenberg,et al.  P2.03b-039 Cell-Free (cf) DNA and cfRNA levels in Plasma of Lung Cancer Patients Indicate Disease Status and Predict Progression: Topic: Biomarkers , 2017 .

[52]  Marilyn M. Li,et al.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[53]  S. Merajver,et al.  Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. , 2016, Clinical biochemistry.

[54]  T. Mitsudomi,et al.  Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. , 2016, The Lancet. Oncology.

[55]  F. Diehl,et al.  Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing , 2016, PloS one.

[56]  Pasquale Pisapia,et al.  Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients. , 2016, Translational lung cancer research.

[57]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer , 2016 .

[58]  M. Erlander,et al.  A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[59]  C. Paweletz,et al.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  S. Gettinger,et al.  Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Anil Vachani,et al.  Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA , 2016, Clinical Cancer Research.

[62]  E. Cortesi,et al.  Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab , 2016, Scientific Reports.

[63]  Suzanne E Dahlberg,et al.  Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. , 2016, JAMA oncology.

[64]  Ash A. Alizadeh,et al.  Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients , 2016, Nature Communications.

[65]  Jie Ma,et al.  A comparative study of EGFR oncogenic mutations in matching tissue and plasma samples from patients with advanced non-small cell lung carcinoma. , 2016, Clinica chimica acta; international journal of clinical chemistry.

[66]  P. Pauwels,et al.  Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool. , 2016, Journal of visualized experiments : JoVE.

[67]  S. Digumarthy,et al.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.

[68]  S. Mortimer,et al.  Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. , 2016 .

[69]  P. Pauwels,et al.  Follow up analysis by exosomal miRNAs in EGFR mutated non-small cell lung cancer (NSCLC) patients during osimertinib (AZD9291) treatment: A potential prognostic biomarker tool. , 2016 .

[70]  A. Barzi,et al.  PD-L1 and HER2 expression in gastric cancer (GC) patients (pts) using cell-free RNA (cfRNA). , 2016 .

[71]  M. Erlander,et al.  Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. , 2016 .

[72]  Ann M. Bailey,et al.  Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  Tae Min Kim,et al.  Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[74]  Juan Wang,et al.  Extracellular miR-1246 promotes lung cancer cell proliferation and enhances radioresistance by directly targeting DR5 , 2016, Oncotarget.

[75]  M. Oudkerk,et al.  Complication rates of CT-guided transthoracic lung biopsy: meta-analysis , 2016, European Radiology.

[76]  Haikuo Zhang,et al.  Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors , 2016 .

[77]  P. Jänne,et al.  Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation‐positive advanced non‐small cell lung cancer (aNSCLC): 134O_PR , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[78]  J. Gartner,et al.  Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients , 2016, Nature Medicine.

[79]  Ash A. Alizadeh,et al.  Integrated digital error suppression for improved detection of circulating tumor DNA , 2016, Nature Biotechnology.

[80]  A. Kohlmann,et al.  Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC) , 2016, PloS one.

[81]  Meizhuo Zhang,et al.  Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance , 2016, Scientific Reports.

[82]  B. Fox,et al.  Immune Monitoring Technology Primer: protein microarray (‘seromics’) , 2016, Journal of Immunotherapy for Cancer.

[83]  Matthew W. Snyder,et al.  Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin , 2016, Cell.

[84]  Zhuqing Jiao,et al.  Radiation-induced miR-208a increases the proliferation and radioresistance by targeting p21 in human lung cancer cells , 2016, Journal of Experimental & Clinical Cancer Research.

[85]  Sin-Ho Jung,et al.  Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) , 2016, Oncotarget.

[86]  Crispin J. Miller,et al.  Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample , 2015, Molecular oncology.

[87]  T. Wurdinger,et al.  Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer , 2015, Oncotarget.

[88]  J Carl Barrett,et al.  EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. , 2015, Lung cancer.

[89]  D. Lin,et al.  Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Pieter Wesseling,et al.  RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics , 2015, Cancer cell.

[91]  K. Pantel,et al.  Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients. , 2015, Cancer cell.

[92]  B. Kermani,et al.  Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA , 2015, PloS one.

[93]  Geoffrey R. Oxnard,et al.  Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients , 2015, Clinical Cancer Research.

[94]  B. Park,et al.  Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. , 2015, Clinical biochemistry.

[95]  Yong He,et al.  Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma. , 2015, The Journal of molecular diagnostics : JMD.

[96]  Toru Kumagai,et al.  Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA. , 2015, Clinical chemistry.

[97]  E. Domany,et al.  Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth , 2015, Cell Death and Differentiation.

[98]  Feng Jiang,et al.  Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer , 2015, Laboratory Investigation.

[99]  S. Ramalingam,et al.  A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-naïve patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation. , 2015 .

[100]  E. Felip,et al.  Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. , 2015, JAMA oncology.

[101]  S. Digumarthy,et al.  Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. , 2015, Cancer discovery.

[102]  P. Jänne,et al.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.

[103]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[104]  T. Mok,et al.  Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy , 2015, Clinical Cancer Research.

[105]  J. Blay,et al.  Detection of tumor ALK status in neuroblastoma patients using peripheral blood , 2015, Cancer medicine.

[106]  J. Wolchok,et al.  Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo , 2015, The Journal of Immunology.

[107]  Chung-Liang Ho,et al.  Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer. , 2014, American journal of respiratory and critical care medicine.

[108]  C. Chouaid,et al.  Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01). , 2014, Lung cancer.

[109]  Stephen J. Salipante,et al.  Performance Comparison of Illumina and Ion Torrent Next-Generation Sequencing Platforms for 16S rRNA-Based Bacterial Community Profiling , 2014, Applied and Environmental Microbiology.

[110]  A. Iafrate,et al.  Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib , 2014, Clinical Cancer Research.

[111]  E. Giovannetti,et al.  Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. , 2014, Cancer treatment reviews.

[112]  N. Girard,et al.  Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002 , 2014, Clinical Cancer Research.

[113]  S. Ren,et al.  Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples , 2014, Translational oncology.

[114]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  Yi-long Wu,et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[116]  R. McCormack,et al.  First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study , 2013, British Journal of Cancer.

[117]  D De Ruysscher,et al.  Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[118]  E. Nexo,et al.  Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays , 2014, BMC Cancer.

[119]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  Marta Di Nicola,et al.  microRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[121]  Christopher M. Hindson,et al.  Absolute quantification by droplet digital PCR versus analog real-time PCR , 2013, Nature Methods.

[122]  W. Dong,et al.  High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. , 2013, European journal of cancer.

[123]  Jesse J. Salk,et al.  Detection of ultra-rare mutations by next-generation sequencing , 2012, Proceedings of the National Academy of Sciences.

[124]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[125]  Kikuya Kato,et al.  Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas , 2011, Clinical Cancer Research.

[126]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[127]  Douglas D. Taylor,et al.  Exosomal microRNA: a diagnostic marker for lung cancer. , 2008, Clinical lung cancer.

[128]  R. Rosell,et al.  Circulating MicroRNA Signatures of Tumor-Derived Exosomes for Early Diagnosis of Non-Small-Cell Lung Cancer. , 2009, Clinical lung cancer.

[129]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[130]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[131]  Zhanjiang Liu.  DNA Sequencing Technologies , 2007 .

[132]  R. C. Coombes,et al.  The Importance of Careful Blood Processing in Isolation of Cell‐Free DNA , 2006, Annals of the New York Academy of Sciences.

[133]  Frank Diehl,et al.  BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions , 2006, Nature Methods.

[134]  R. Chiu,et al.  EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. , 2004, Clinical chemistry.

[135]  Sofamor Danek,et al.  SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED) , 2004 .

[136]  M. Busch,et al.  Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma , 2001, Transfusion.